Viatris Inc
VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/303% below fair value
$19.63−0.25 (-1.26%)
Close on Nov 20, 2026Market cap $22.55BP/E –Yield 2.45%
Viatris UTB Reductions — Lapse of Statute of Limitations by Year
UTB Reductions — Lapse of Statute of Limitations ($M)
Viatris UTB Reductions — Lapse of Statute of Limitations: $19M in FY2025, up 41.8% from a year earlier.
Latest, FY2025
19
Period ended Dec 31, 2025
Change on a year earlier
+41.8%
13.4 in FY2024
History
10 years
Since FY2016
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: SEC Form 10-K (2026-02-26) ↗
Reported in SEC Form 10-K Income Taxes Note.
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UTB Reductions — Lapse of Statute of Limitations ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19 | +41.8% | SEC Form 10-K (2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 13.4 | +3.1% | SEC Form 10-K (2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 13 | +584.2% | SEC Form 10-K (2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 1.90 | -72.9% | SEC Form 10-K (2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 7 | 0.0% | SEC Form 10-K (2024-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 7 | – | SEC Form 10-K (2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | SEC Form 10-K (2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 0 | -100.0% | SEC Form 10-K (2023-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 34.9 | -50.6% | SEC Form 10-K (2022-02-28) ↗ |
| FY2016 | Dec 31, 2016 | 70.7 | – | SEC Form 10-K (2021-03-01) ↗ |
Cite this data
StockData. (2026). Viatris UTB Reductions — Lapse of Statute of Limitations ($M), annual FY2016–FY2025 [Data set]. Compiled from Viatris SEC filings and investor materials. https://stockdatahq.com/stocks/vtrs/kpis/utb-dec-lapse
See every metric in the Viatris KPI table. Data updated Nov 16, 2026.
See a number that looks wrong?